180 related articles for article (PubMed ID: 16934051)
1. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
5. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
6. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2008 May; 64(5):511-9. PubMed ID: 18197403
[TBL] [Abstract][Full Text] [Related]
8. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe.
Bachmann K; White D; Jauregui L; Schwartz JI; Agrawal NG; Mazenko R; Larson PJ; Porras AG
J Clin Pharmacol; 2003 Oct; 43(10):1082-90. PubMed ID: 14517190
[TBL] [Abstract][Full Text] [Related]
10. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman JT; Schröder MT; Neuvonen PJ
Eur J Clin Pharmacol; 2008 Jan; 64(1):17-24. PubMed ID: 17955229
[TBL] [Abstract][Full Text] [Related]
11. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
[TBL] [Abstract][Full Text] [Related]
12. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 Sep; 63(9):829-36. PubMed ID: 17618427
[TBL] [Abstract][Full Text] [Related]
13. Pantoprazole lacks induction of CYP1A2 activity in man.
Hartmann M; Zech K; Bliesath H; Steinijans VW; Koch H; Wurst W; Mascher H
Int J Clin Pharmacol Ther; 1999 Apr; 37(4):159-64. PubMed ID: 10235417
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):157-65. PubMed ID: 18816299
[TBL] [Abstract][Full Text] [Related]
15. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole weakly inhibits CYP1A2 activity in man.
Rost KL; Fuhr U; Thomsen T; Zaigler M; Brockmöller J; Bohnemeier H; Roots I
Int J Clin Pharmacol Ther; 1999 Nov; 37(11):567-74. PubMed ID: 10584979
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
18. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
19. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
20. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
Henney HR; Fitzpatrick A; Stewart J; Runyan JD
Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
